(redirected from Nicotinic acetylcholine receptor)
Also found in: Medical, Wikipedia.
Related to Nicotinic acetylcholine receptor: Muscarinic acetylcholine receptor


 (nĭk′ə-tĭn′ĭk, -tē′nĭk)
1. Of or relating to nicotine.
2. Of or relating to niacin.


(ˌnɪk əˈtɪn ɪk, -ˈti nɪk)

1. of, pertaining to, or containing nicotine.
2. related to or imitating the effects of nicotine.


[ˌnikəˈtɪnɪk] ADJ nicotinic acidácido m nicotínico
References in periodicals archive ?
Esbupropion is the S-enantiomer of bupropion, a dopamine and norepinephrine reuptake inhibitor and nicotinic acetylcholine receptor antagonist which also serves to increase the bioavailability of dextromethorphan.
Cytisine, a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor, is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe for more than 15 years.
The company said cytisine is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor.
Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia.
Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 (a7) nicotinic acetylcholine receptor.
Some 2,500 years after Hippocrates observed a hereditary tendency for epilepsy, researchers discovered the first causative gene, neuronal nicotinic acetylcholine receptor alpha 4 subunit (CHRNA4), in 1995.
Nicotine is a nicotinic acetylcholine receptor (nAChR) agonist with parasympathomimetic effects.
Therefore we hypothesized that imidacloprid toxicity is not only the result of nicotinic acetylcholine receptor inhibition but also the result of a number of physiological alterations in nervous and other insect tissues.
Spinosad is a neurotoxin that targets the nicotinic acetylcholine receptor and the GABA receptors, and causes cessation of feeding followed later by paralysis and death (Salgado 1998; Crouse et al.
14) Varenicline as a partial agonist of [alpha]4[beta]2 nicotinic acetylcholine receptor, through intrinsic activation, results in a moderate increase in dopamine levels in the mesolimbic area of brain.
The team found that the redeye gene encodes a subunit of the nicotinic acetylcholine receptor.
Varenicline is a [alpha]4[beta]2 nicotinic acetylcholine receptor partial agonist which is used for the cessation of smoking (4).